Xilio therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Waltham, mass., june 03, 2025 (globe newswire) -- xilio therapeutics, inc. (nasdaq: xlo), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective june 1, 2025, the company granted non-qualified stock options to purchase 181,300 shares of its common stock to five new employees under xilio therapeutics' 2022 inducement stock incentive plan.
NDAQ Ratings Summary
NDAQ Quant Ranking